TORONTO, Canada (February 7, 2017) — PharmaCielo Ltd. is pleased to announce the appointment of Henning von Koss to its board of directors. Mr. von Koss has decades of professional experience in multiple sectors that have included health care services and products as well as industrial products.
During his 27 years with Bayer, Mr. von Koss Bayer’s president and head of health care for the Andean countries where he led an extensive team in directing all the company’s functions and activities throughout the region and as senior vice president of Latin America for Bayer Material Science, based in Colombia and then Venezuela. Mr. von Koss also held numerous management positions with Bayer in Brazil, Germany and Poland.
“Mr. von Koss brings to our Board of Directors tremendous experience in the international business community, as well as in the health care sector,” said PharmaCielo Ltd. chairman Simon Langelier. “His international business experience and insights on the global health care sector will make a significant contribution to our continued growth and market development.”
Most recently, Mr. von Koss served as COO of HAPVIDA, the third largest managed care organization in Brazil with 20 hospitals, 70 clinics, 50 labs, and more than 17,000 employees. In addition to his experience with Bayer, he has served as CEO of Industrial Levorin, a family-owned producer of tires and tubes, COO of Amil Assistencia Medica Internacional, the largest managed care organization in Brazil, and CEO of Medial Saude (Grupo AMIL), another large managed care organization in Brazil.
Mr. von Koss received a Bachelor’s degree in Business Administration from Pontificia Universidade Catolica in São Paulo, Brazil. He has dual Brazilian / German nationality and is fluent in five languages, German, Portuguese, English, Spanish and Polish.
This announcement comes shortly after PharmaCielo announced its partnership with Cooperativa Caucannabis, a cooperative comprised of 53 regional farmers, to develop commercial cannabis cultivation in the historic cannabis producing Cauca region of Colombia. The mayors of these five communities, together with the full support of the Government of Colombia, encouraged the creation of this innovative initiative to eliminate illegal cannabis production and unite the region’s cultivators in an association that will jointly apply for legal cultivation licensure with PharmaCielo under the terms of recently announced Colombian legislation.
About PharmaCielo Ltd.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.